References and Notes
-
3a
Yang CS.
Chung JY.
Yang G.
Chhabra SK.
Lee MJ.
J. Nutr.
2000.
130:
p.472S
-
3b
Tosetti F.
Ferrari N.
De Flora S.
Albini A.
FASEB J.
2002,
16:
2
-
4a
Nam S.
Smith DM.
Dou QP.
J. Biol. Chem.
2001,
276:
13322
-
4b
Smith DM.
Daniel KG.
Wang Z.
Guida WC.
Chan TH.
Dou QP.
Proteins: Struct. Funct. Bioinform.
2004,
54:
58
-
4c
Jankun J.
Selman SH.
Swiercz R.
Skrzypczak-Jankun E.
Nature
1997,
387:
561
-
4d
Sachinidis A.
Hescheler J.
Drug News Perspect.
2002,
15:
432
-
5a
Rensburg H.
Heerden PS.
Ferreira D.
J. Chem. Soc., Perkin Trans. 1
1997,
3415
-
5b
Jew S.-S.
Lim D.-y.
Bae S.-y.
Kim H.-a.
Kim J.-h.
Lee J.
Park H.-g.
Tetrahedron: Asymmetry
2002,
13:
715
-
5c
Nay B.
Arnaudinaud V.
Peyrat JF.
Nuhrich A.
Deffieux G.
Merillon JM.
Vercauteren J.
Eur. J. Org. Chem.
2000,
1279
-
5d
Zaveri NT.
Org. Lett.
2001,
3:
843
-
6a
Li L.
Chan TH.
Org. Lett.
2001,
3:
739
-
6b
Anderson JC.
Headley C.
Stapleton PD.
Taylor PW.
Tetrahedron
2005,
61:
7703
- 7
Miles CO.
Main L.
Nicholson BK.
Aust. J. Chem.
1989,
42:
1103
- 8
Murray RW.
Jeyaram R.
J. Org. Chem.
1985,
50:
2847
-
9a
Kaus GA.
Molina T.
Walling JA.
J. Chem. Soc., Chem. Commun.
1986,
1568
-
9b
Luengo JI.
Konialian-Beck A.
Rozamus LW.
Holt DA.
J. Org. Chem.
1994,
59:
6512
1 Current Address: Cancer Research Lab. Hanno Advanced Research Lab., Taiho Pharmaceutical Co., Ltd. 1-27, Misugidai, Hanno-shi, Saitama, 357-8527, Japan.
2 Current Address: Fukaya Plant Tokyo Kasei Kogyo Co., LTD. 725 Kashiai Fukaya-shi, Saitama 366-0816, Japan.
10 Procedure for the reductive cyclization to give (2R*,3R*)-3,4-dihydro-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-2H-chromen-3-yl 3,4,5-trimethoxybenzoate (14a): To a stirred solution of 2a (17 mg, 0.024 mmol) in CH2Cl2 (0.5 mL) was added a solution of triethylsilane (10%) and trifluoroacetic acid (25%) in CH2Cl2 at 0 °C. The reaction mixture was then warmed to r.t. for 4 h. Toluene (5 mL) was added to the reaction mixture and the volatile components were removed by evaporation in vacuo. The product was purified using column chromatography on silica gel, eluting with hexane-EtOAc (5:1 → 2:1) to afford 2a (12 mg, 0.021 mmol, 88%) as a white solid; mp 155-157 °C; IR (solid) 2940, 2839, 1717, 1621, 1592 cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.17 (s, 2 H), 6.70 (s, 2 H), 6.25 (d, J = 1.9 Hz, 1 H), 6.12 (d, J = 1.9 Hz, 1 H), 5.67 (m, 1 H), 5.09 (s, 1 H), 3.86 (s, 3 H), 3.81 (s, 6 H), 3.80 (s, 3 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.72 (s, 6 H), 3.05 (d, J = 3.4 Hz, 2 H); 13C NMR (100 MHz, CDCl3): δ = 165.1, 159.7, 158.8, 155.5, 153.1, 152.8, 142.5, 137.9, 133.3, 125.1, 107.2, 103.9, 100.1, 93.2, 91.9, 77.7, 68.6, 60.9, 60.8, 56.2, 56.0, 55.4, 25.9.
11
(±)-Epigallocatechin gallate(1): mp 220 °C (dec); 1H NMR [400 MHz, acetone-d
6-D2O (2:1)]: δ = 6.89 (s, 2 H), 6.53 (s, 2 H), 5.90 (d, J = 2.4 Hz, 1 H), 5.89 (d, J = 2.4 Hz, 1 H), 4.89 (s, 1 H), 5.28 (s, 1 H), 2.87 (dd, J = 17.5, 4.4 Hz, 1 H), 2.78 (dd, J = 17.5, 1.6 Hz, 1 H); 13C NMR [100 MHz, acetone-d
6-D2O (2:1)]: δ = 212.2, 167.2, 157.3, 156.8, 146.2, 145.9, 139.3, 133.1, 130.6, 121.3, 110.2, 106.8, 98.9, 96.6, 95.7, 78.1, 70.3, 26.6. The analytical data (1H and 13C NMR) of 1 was identical to the commercially available authentic sample [(-)-EGCG, Wako Pure Chemical industries, Ltd.].